Condition

Brain Diseases

ClinicalTrials.gov condition label

Clinical trials50
Recruiting11
Common interventions25
Lead sponsors shown15

Clinical trials

50 shown
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical ActivityNCT07324330 · 2025-12-04
RECRUITING
Slow-SPEED: Slowing Parkinson's Early Through Exercise DosageNCT06993142 · 2025-09-01
RECRUITING
University of Central Florida CereBankNCT06876857 · 2025-02-25
RECRUITING
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-NetherlandsNCT06193252 · 2024-01-15
RECRUITING
A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, ChinaNCT05886114 · 2023-05-28
RECRUITING
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's DementiaNCT06088121 · 2023-05-15
RECRUITING
Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle ControlNCT07056361 · 2022-12-16
RECRUITING
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerNCT05386108 · 2022-08-31
RECRUITING
Clinical Indicators and Brain Image Data: a Study Based on Kailuan CohortNCT05453877 · 2022-08-01
RECRUITING
Biobank and Brain Health in Bordeaux.NCT05322343 · 2022-03-22
RECRUITING
CUHK Brain Health Longitudinal StudyNCT03592563 · 2019-07-01
RECRUITING
NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.NCT07063810 · 2025-06-30
COMPLETED
Digital Diagnostics and Intervention Services for Parkinson's DiseaseNCT06534177 · 2024-10-15
UNKNOWN
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)NCT05921929 · 2024-05-02
WITHDRAWN
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationNCT05321498 · 2023-06-01
WITHDRAWN
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486 · 2023-02-28
ACTIVE_NOT_RECRUITING
An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387 · 2023-02-21
TERMINATED
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789 · 2022-10-10
ACTIVE_NOT_RECRUITING
Technology of Intracranial Pressure Estimation by Single-Channel EEG in Brain DiseaseNCT05609071 · 2022-03-22
UNKNOWN
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976 · 2022-02-28
COMPLETED
Harmony at Home: A Pilot Telehealth Program for Rural ADRD CaregiversNCT05202223 · 2022-01-15
COMPLETED
Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's DiseaseNCT04871464 · 2021-11-11
UNKNOWN
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care SystemsNCT05080777 · 2021-09-28
COMPLETED
The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) StudyNCT05007353 · 2021-08-23
COMPLETED
Impact of COVID-19 Vaccines on Cerebrovascular HealthNCT04992195 · 2021-07-05
COMPLETED
Personalized Parkinson Project PSP CohortNCT05501431 · 2021-05-01
COMPLETED
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese PopulationNCT05527288 · 2021-01-28
COMPLETED
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)NCT04640077 · 2020-11-23
COMPLETED
Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patientsNCT04378621 · 2020-10-01
UNKNOWN
The Personalized Parkinson Project De Novo CohortNCT04985539 · 2020-08-29
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's DiseaseNCT04445831 · 2019-07-31
COMPLETED
Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the SmartphoneNCT03762902 · 2019-04-30
TERMINATED
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF InfusionsNCT04228653 · 2019-03-20
UNKNOWN
Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical StudyNCT03775538 · 2018-07-05
COMPLETED
HIRREM for Pre-HypertensionNCT03332043 · 2018-03-01
WITHDRAWN
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's DiseaseNCT03295786 · 2017-09-26
COMPLETED
Neurostimulation for Dysphagia in Parkinson's DiseaseNCT03253354 · 2017-08-01
COMPLETED
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseNCT03065192 · 2017-05-11
COMPLETED
Long Term Survivors of High-grade Glioma and Their CaregiversNCT02965144 · 2016-12-01
COMPLETED
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and FitbitNCT02910921 · 2016-11-01
COMPLETED
CNS Tau Kinetics in Healthy Aging and Alzheimer's DiseaseNCT03938870 · 2015-08-18
COMPLETED
Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)NCT02696603 · 2015-03-01
ACTIVE_NOT_RECRUITING
The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-ADNCT01696591 · 2012-03-01
UNKNOWN
Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's DiseaseNCT01662414 · 2011-04-01
COMPLETED
Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)NCT00537017 · 2007-11-23
COMPLETED
Dyskinesia in Parkinson's Disease (Study P04501)NCT00406029 · 2006-11-20
COMPLETED
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive ImpairmentNCT00240695 · 2003-05-01
COMPLETED
A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseNCT00291421 · 2002-07-01
COMPLETED
A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseNCT00216502 · 2001-08-01
COMPLETED
Brain Tissue Collection for Neuropathological StudiesNCT00001260 · 1990-05-29
TERMINATED

Common interventions

PlaceboDRUG5DonanemabDRUG3Increase of physical activity volume and intensity with the use of a motivational smartphone applicationBEHAVIORAL3Renishaw Drug Delivery SystemDEVICE3XPro1595DRUG3Cerebral Dopamine Neurotrophic FactorDRUG2galantamine hydrobromideDRUG2L-dopaDRUG2Other Parkinson's Disease treatmentsDRUG2PlaceboOTHER2PreladenantDRUG2Self-Guided InterventionBEHAVIORAL2Verily Study WatchDEVICE2AbemaciclibDRUG1ACI-35.030BIOLOGICAL1Ambient Nature SoundsOTHER1ATNC BN-V1DEVICE1ATNC BN-V2DEVICE1ATNC MDD-V1 (Real TMS + Real Cog)DEVICE1ATNC MDD-V1 (Sham TMS + Real Cog)DEVICE1Caregiving During Crisis (Educational Program)BEHAVIORAL1DexamethasoneDRUG1DexterityBEHAVIORAL1Direct cortical stimulation and deep brain stimulation of motor thalamusDEVICE1Drug: [18F]florbetabenDRUG1

Trial status mix

COMPLETED23
RECRUITING11
UNKNOWN6
ACTIVE_NOT_RECRUITING4
TERMINATED3
WITHDRAWN3

Phase mix

NA15
PHASE211
PHASE17
PHASE34
PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.